We’re excited to announce that Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site


Clone, Culture, Assay and Select Top Clones
on a Single Platform

BEYOND TITER: Identify Top Producers with Favorable Product Quality Attributes within 5 Days of Cloning

BEYOND TITER: Identify Top Producers with Favorable Product Quality Attributes within 5 Days of Cloning

CHO cell line selection is a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics. The Opto® CLD workflow on the Beacon® and Beacon Select™ systems accelerates early CLD by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, 5-day automated process. Hear about capabilities of on-chip detection that pinpoints best clones early on.


The Opto® Cell Line Development Workflow

Cell Line Development (CLD) on the Beacon® and Beacon Select™ optofluidic systems enables high throughput cloning, screening, and selection of top-performing CHO cell lines in just days. Used globally by leading pharmaceutical companies and CDMOs, the Beacon systems’ industry-leading technology delivers unrivaled speed and efficiency to cell line development workflows. The Opto® CLD workflow has enabled customers to select clones with higher titers than traditional methods (Customer Spotlight: Catalent), increase throughput by 4X while reducing their cell line development timeline by up to 50% (Customer Spotlight: Mycenax), and recover clones with >99% monoclonality assurance to support FDA IND regulatory filings (Application Note: FDA Accepted IND). In addition, the Opto™ Assure quality assays enable users to select clones with favorable product quality attributes within 5 days of cloning to reduce overall costs, improve the probability of success, and further shorten timelines by selecting top clones for scale up.

View Datasheet

Deliver the best cell lines

Set your IND up for success by getting FDA-accepted monoclonality assurance in just days.

  • GSK
    Robyn Emmins, Group Leader
    We’ve been able to screen more molecules per project and clones per lead, meaning we can engage with our discovery colleagues earlier.
customer webinars

Workflow In Action

See how our customers apply our CLD workflow to streamline cell line development and get to the clinic faster.


Thermo Fisher Scientific on: “Leveraging Innovative Technologies to Accelerate Biologics Development”

Watch More:

Fireside chat with Catalent, University of Queensland, and Amgen

Select for Even the Most Complex Molecules in Just Days​

Replace 8-12 weeks of challenging well plate steps with Opto® CLD on the Beacon® and Beacon Select™ optofluidic systems.​

Cell Line Development Workflow

Screen thousands of clones in parallel and select top clones for even non-traditional antibody molecules, like bi-specifics.

Selection Based on Product Quality, Not Just Productivity​​

Get to production faster with Opto™ Assure for early manufacturability assessment.​​


CLD Aggregation Assay

Opto™ Assure minimizes risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality. Opto Assure assay for aggregation enables direct detection of product aggregates within days of single cell cloning. This lets you confidently identify and select clones that secrete high-quality complex molecules and develop better production cell lines faster. ​​

>99% monoclonality assurance

Get >99% monoclonality assurance with a single, automated round of cloning.

The Berkeley Lights Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance –  which is equivalent to four rounds of limiting dilution!

See independent validation by Le, K et al. Amgen.

Bulk stable pool to rare, top quality clones in one week​

Access to more relevant cell diversity with Selective Cell Cloning.​

Selective Cell Cloning with Opto CLD lets you screen up to 100,000 cells in a single 5-day workflow, enabling access to more relevant cell diversity than conventional methods for cell line development. Gently enrich transfected pools by identifying and cloning only cells that are viable and express your protein of interest. With Selective Cell Cloning, you can eliminate weeks of mini-pool processing by enabling deeper screening of bulk stable pools.​


FDA-accepted clonality assurance for a successful IND​

The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for definitive evidence of monoclonality to support regulatory approvals.

See Application Note

Export the best from 1000s of clones

The Opto CLD Workflow enables selection of top clones by measuring growth over multiple days of on-chip culture and secretion titers using quantitative assays for both traditional and non-traditional antibodies.

  • Measure antibody production from 1000s of clones
  • Quantify secretion titers and specific (per-cell) productivity using the SpotLight™ Human Fc and SpotLight™ Human Kappa reagents
  • Enrich and recover top-secreting clones for scale-up

SpotLight assay: Simultaneous, quantitative antibody titer measurements on thousands of clones (LEFT). Clones selected based on titer measurements on the Beacon system had 1.5–3-fold higher titers than clones selected using traditional clone picking technology when scaled up to shake flask fed-batch cultures (RIGHT). ©2019 Catalent, Inc. All rights reserved.

Related Resources

View All Cell Line Development Resources
Cell Line Development

DATASHEET: Opto® Cell Line Development Workflow

  • Selective Cell Cloning for better clones and accelerated campaign timelines
  • Custom Productivity Assay for selection of cell lines expressing a wide range of therapeutic proteins and vaccines
Cell Line Development Beacon System

BROCHURE: Beacon Select™ Optofluidic System for CLD

  • Approximately half the price of the 4-chip Beacon system
  • A 2-chip automated optofluidic system, similar to the 4-chip Beacon® optofluidic system, which provides well-established workflows that have been adopted by ~130 customers
  • Throughput scaled to meet the needs of small to mid-sized biopharma and CDMO/CRO companies
Cell Line Development

Brochure: Get to Market Faster with the Opto CLD Workflow

Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster. 

Cell Line Development

Brochure: Increase CDMO Revenue with the Opto CLD Workflow

Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business. 

Cell Line Development

Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing

Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.

Ready to discuss access options?

Ask us about purchase options including our new TechAccess Subscription.*

*Available in select regions